步長製藥(603858.SH):注射用帕瑞昔布鈉獲批上市
格隆匯11月29日丨步長製藥(603858.SH)公佈,公司全資子公司山東丹紅製藥有限公司(“山東丹紅”)近日收到國家藥品監督管理局核准簽發的關於注射用帕瑞昔布鈉的《藥品註冊證書》。
注射用帕瑞昔布鈉用於手術後疼痛的短期治療。在決定使用選擇性環氧化酶-2(COX-2)抑制劑前,應評估患者的整體風險。
根據米內網數據2018年至2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,注射用帕瑞昔布鈉銷售額依次為128863萬元、199416萬元、219796萬元。
截至公吿日,公司在注射用帕瑞昔布鈉上投入的研發費用約1906.62萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.